Thermo Fisher Scientific Inc. $TMO Shares Acquired by Applied Finance Capital Management LLC

Key Points

• Applied Finance Capital Management LLC increased its stake in Thermo Fisher Scientific Inc. by 9.6%, owning a total of 30,928 shares valued at approximately $12.54 million.
• In its latest quarterly earnings report, Thermo Fisher exceeded expectations with a net revenue of $10.86 billion and earnings per share (EPS) of $5.36, surpassing analyst estimates of $5.22.
• Wall Street analysts remain optimistic about Thermo Fisher, with a consensus rating of "Moderate Buy" and an average price target of $589.10.

Applied Finance Capital Management LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,928 shares of the medical research company's stock after acquiring an additional 2,708 shares during the quarter. Applied Finance Capital Management LLC's holdings in Thermo Fisher Scientific were worth $12,540,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Nuveen LLC acquired a new stake in Thermo Fisher Scientific in the first quarter worth about $532,360,000. EdgePoint Investment Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $172,139,000. Cohen Investment Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 6,655.5% in the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after acquiring an additional 331,180 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after acquiring an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co raised its holdings in Thermo Fisher Scientific by 6,773.5% during the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock worth $143,309,000 after purchasing an additional 283,810 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $536.75 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The firm's 50 day simple moving average is $494.18 and its 200-day simple moving average is $449.02. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market cap of $202.68 billion, a P/E ratio of 31.04, a price-to-earnings-growth ratio of 2.87 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TMO. Barclays lifted their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a research report on Thursday, October 2nd. HSBC reaffirmed a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Tuesday. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Finally, Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $589.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.